Cue Biopharma, Inc. (CUE) stock
CUENasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.50−1.16 (-6.22%)
Close on Nov 12, 2026Market cap $127.13MP/E –Yield –
Cue Biopharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Cue Biopharma's profit margin for the twelve months ending Jun 30, 2026 was -435.8%. For fiscal 2025 it was -96.9%, against -438.0% the year before. The highest annual figure on record is -96.9% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -96.9% | +341.1 |
| FY2024 | Dec 31, 2024 | -438.0% | +486.1 |
| FY2023 | Dec 31, 2023 | -924.1% | +3333.7 |
| FY2022 | Dec 31, 2022 | -4257.8% | −3962.3 |
| FY2021 | Dec 31, 2021 | -295.6% | +1124.2 |
| FY2020 | Dec 31, 2020 | -1419.8% | −358.6 |
| FY2019 | Dec 31, 2019 | -1061.2% | +2350.4 |
| FY2018 | Dec 31, 2018 | -3411.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -1943.2% | −1656.1 |
| Q1 FY2026 | Mar 31, 2026 | -91.1% | +2820.3 |
| Q4 FY2025 | Dec 31, 2025 | 7.2% | +609.8 |
| Q3 FY2025 | Sep 30, 2025 | -346.6% | −87.0 |
| Q2 FY2025 | Jun 30, 2025 | -287.1% | +95.5 |
| Q1 FY2025 | Mar 31, 2025 | -2911.4% | −2192.3 |
| Q4 FY2024 | Dec 31, 2024 | -602.5% | +135.2 |
| Q3 FY2024 | Sep 30, 2024 | -259.6% | +264.5 |
| Q2 FY2024 | Jun 30, 2024 | -382.7% | +571.4 |
| Q1 FY2024 | Mar 31, 2024 | -719.1% | +6291.1 |
| Q4 FY2023 | Dec 31, 2023 | -737.7% | +8925.8 |
| Q3 FY2023 | Sep 30, 2023 | -524.0% | +15586.2 |
| Q2 FY2023 | Jun 30, 2023 | -954.1% | +49845.9 |
| Q1 FY2023 | Mar 31, 2023 | -7010.2% | −5584.7 |
| Q4 FY2022 | Dec 31, 2022 | -9663.6% | −9562.0 |
| Q3 FY2022 | Sep 30, 2022 | -16110.3% | −15567.8 |
| Q2 FY2022 | Jun 30, 2022 | -50800.0% | −50424.7 |
| Q1 FY2022 | Mar 31, 2022 | -1425.5% | −620.3 |
| Q4 FY2021 | Dec 31, 2021 | -101.6% | +2234.3 |
| Q3 FY2021 | Sep 30, 2021 | -542.5% | +882.4 |
| Q2 FY2021 | Jun 30, 2021 | -375.3% | +632.4 |
| Q1 FY2021 | Mar 31, 2021 | -805.2% | +619.0 |
| Q4 FY2020 | Dec 31, 2020 | -2335.9% | −1486.1 |
| Q3 FY2020 | Sep 30, 2020 | -1424.9% | −714.5 |
| Q2 FY2020 | Jun 30, 2020 | -1007.7% | −105.2 |
| Q1 FY2020 | Mar 31, 2020 | -1424.2% | +1620.9 |
| Q4 FY2019 | Dec 31, 2019 | -849.8% | +2665.4 |
| Q3 FY2019 | Sep 30, 2019 | -710.4% | +2086.7 |
| Q2 FY2019 | Jun 30, 2019 | -902.6% | +3341.6 |
| Q1 FY2019 | Mar 31, 2019 | -3045.1% | – |
| Q4 FY2018 | Dec 31, 2018 | -3515.2% | – |
| Q3 FY2018 | Sep 30, 2018 | -2797.1% | – |
| Q2 FY2018 | Jun 30, 2018 | -4244.2% | – |
See a number that looks wrong?